Randomized, Open, Controlled, Multicenter Phase III Clinical Study of Fluzoparib in Combination With Apatinib Versus Investigator-Selected Chemotherapy for HRD-Positive/HER2-negative Advanced Breast Cancer

This trial tests a maintenance treatment strategy for women with HER2-negative, HRD-positive metastatic breast cancer who have already benefited from chemotherapy. HRD-positive means there is a DNA repair defect in the tumor that may respond to specific targeted drugs. The study evaluates whether continuing a targeted maintenance therapy after an initial chemo response extends how long the disease stays controlled. **You may be eligible if...** - You are a woman aged 18–70 with HER2-negative, HRD-positive metastatic breast cancer - Your tumor has a BRCA mutation or a high HRD score (42+) - You achieved a clinical benefit (tumor shrinkage or stabilization) after 6–8 cycles of chemo - You have received no more than two prior lines of chemotherapy for metastatic disease **You may NOT be eligible if...** - Your tumor is HER2-positive or HRD-negative - You have not responded to initial chemotherapy - You have received more than two prior lines of chemotherapy - Your general health or organ function is too poor Talk to your doctor to see if this trial is right for you.